New Trends in the Standard of Care for Initial Therapy of Acute Myeloid Leukemia

被引：28

作者：

Fernandez, Hugo F. ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2010年

关键词：

D O I：

10.1182/asheducation-2010.1.56

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

In younger patients with acute myeloid leukemia (AML), initial treatment has provided very good control of the disease. Induction therapy has used combination chemotherapy, with anthracycline and cytarabine as the foundation. Recent trials support dose intensification of anthracycline in induction. Intensive postremission therapy further contributes to improving survival. The addition of targeted therapy with gemtuzumab ozogamicin to standard therapy has not improved on these outcomes. Newer agents targeted to specific molecular abnormalities or survival mechanisms in the leukemic cell are being studied as future additions to the current standard therapy.

引用

页码：56 / 61

页数：6

共 48 条

[11] Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461 [J].

Byrd, JC ;

Ruppert, AS ;

Mrózek, K ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenatti, MJ ;

Stamberg, J ;

Koduru, PRK ;

Moore, JO ;

Mayer, RJ ;

Davey, FR ;

Larson, RA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1087-1094

[12] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].

Cassileth, PA ;

Harrington, DP ;

Appelbaum, FR ;

Lazarus, HM ;

Rowe, JM ;

Paietta, E ;

Willman, C ;

Hurd, DD ;

Bennett, JM ;

Blume, KG ;

Head, DR ;

Wiernik, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656

[13] Randomized comparison of double induction and timed-sequential induction to a "3+7" induction in adults with AML:: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study [J].

Castaigne, S ;

Chevret, S ;

Archimbaud, E ;

Fenaux, P ;

Bordessoule, D ;

Tilly, H ;

de Revel, T ;

Simon, M ;

Dupriez, B ;

Renoux, M ;

Janvier, M ;

Micléa, JM ;

Thomas, X ;

Bastard, C ;

Preudhomme, C ;

Bauters, F ;

Degos, L ;

Dombret, H .

BLOOD, 2004, 104 (08) :2467-2474

[14] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].

Cornelissen, Jan J. ;

van Putten, Wim L. J. ;

Verdonck, Leo F. ;

Theobald, Matthias ;

Jacky, Emanuel ;

Daenen, Simon M. G. ;

Kooy, Marinus van Marwijk ;

Wijermans, Pierre ;

Schouten, Harry ;

Huijgens, Peter C. ;

van der Lelie, Hans ;

Fey, Martin ;

Ferrant, Augustin ;

Maertens, Johan ;

Gratwohl, Alois ;

Lowenberg, Bob .

BLOOD, 2007, 109 (09) :3658-3666

[15]

De Angelo DJ, 2002, BLOOD, V100, p198A

[16]

DILLMAN RO, 1991, BLOOD, V78, P2520

[17] Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype:: A cancer and leukemia group B study [J].

Farag, SS ;

Ruppert, AS ;

Mrózek, K ;

Mayer, RJ ;

Stone, RM ;

Carroll, AJ ;

Powell, BL ;

Moore, JO ;

Pettenati, MJ ;

Koduru, PRK ;

Stamberg, J ;

Baer, MR ;

Block, AW ;

Vardiman, JW ;

Kolitz, JE ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :482-493

[18] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

[19] Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5) [J].

Garrido, SM ;

Appelbaum, FR ;

Willman, CL ;

Banker, DE .

EXPERIMENTAL HEMATOLOGY, 2001, 29 (04) :448-457

[20] An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells [J].

Guzman, Monica L. ;

Rossi, Randall M. ;

Neelakantan, Sundar ;

Li, Xiaojie ;

Corbett, Cheryl A. ;

Hassane, Duane C. ;

Becker, Michael W. ;

Bennett, John M. ;

Sullivan, Edmund ;

Lachowicz, Joshua L. ;

Vaughan, Andrew ;

Sweeney, Christopher J. ;

Matthews, William ;

Carroll, Martin ;

Liesveld, Jane L. ;

Crooks, Peter A. ;

Jordan, Craig T. .

BLOOD, 2007, 110 (13) :4427-4435

← 1 2 3 4 5 →